Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity

Ravibhushan Singh, Jeff L. Browning, Ralph Abi-Habib, Kevin Wong, Simon A. Williams, Rosemina Merchant, Samuel R Denmeade, Thomas J. Buckley, Arthur E. Frankel

Research output: Contribution to journalArticle

Abstract

Native proaerolysin is a channel-forming bacterial protoxin that binds to cell-surface receptors and then is activated by furin or furin-like proteases. We genetically engineered proaerolysin by replacing the furin-cleavage sequence with a prostate-specific antigen-selective sequence. The recombinant modified proaerolysin was expressed and purified from Aeromonas salmonicida in good yields and purity. Recombinant modified proaerolysin had no furin sensitivity and markedly increased prostate-specific antigen sensitivity relative to wild-type proaerolysin. Human prostate cancer cells were significantly more sensitive to recombinant modified proaerolysin in the presence of active prostate-specific antigen when compared with the absence of prostate-specific antigen or the presence of potent prostate-specific antigen inhibitors. Most normal human cells with the exception of prostate and renal epithelial cells showed very low sensitivity to recombinant modified proaerolysin. Our results suggest that recombinant modified proaerolysin is a potent prostate-specific antigen-sensitive protoxin that deserves further development for regional therapy of benign and malignant prostate growths.

Original languageEnglish (US)
Pages (from-to)809-816
Number of pages8
JournalAnti-Cancer Drugs
Volume18
Issue number7
DOIs
StatePublished - Aug 2007

Fingerprint

Prostate-Specific Antigen
Peptide Hydrolases
Furin
Prostate
Aeromonas salmonicida
proaerolysin
Cell Surface Receptors
Prostatic Neoplasms
Epithelial Cells
Kidney
Growth

Keywords

  • Proaerolysin
  • Prostate cancer
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Singh, R., Browning, J. L., Abi-Habib, R., Wong, K., Williams, S. A., Merchant, R., ... Frankel, A. E. (2007). Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anti-Cancer Drugs, 18(7), 809-816. https://doi.org/10.1097/CAD.0b013e3280bad82d

Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. / Singh, Ravibhushan; Browning, Jeff L.; Abi-Habib, Ralph; Wong, Kevin; Williams, Simon A.; Merchant, Rosemina; Denmeade, Samuel R; Buckley, Thomas J.; Frankel, Arthur E.

In: Anti-Cancer Drugs, Vol. 18, No. 7, 08.2007, p. 809-816.

Research output: Contribution to journalArticle

Singh, R, Browning, JL, Abi-Habib, R, Wong, K, Williams, SA, Merchant, R, Denmeade, SR, Buckley, TJ & Frankel, AE 2007, 'Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity', Anti-Cancer Drugs, vol. 18, no. 7, pp. 809-816. https://doi.org/10.1097/CAD.0b013e3280bad82d
Singh, Ravibhushan ; Browning, Jeff L. ; Abi-Habib, Ralph ; Wong, Kevin ; Williams, Simon A. ; Merchant, Rosemina ; Denmeade, Samuel R ; Buckley, Thomas J. ; Frankel, Arthur E. / Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. In: Anti-Cancer Drugs. 2007 ; Vol. 18, No. 7. pp. 809-816.
@article{c23f9b0c6ca24bbc8fec69260977a7e5,
title = "Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity",
abstract = "Native proaerolysin is a channel-forming bacterial protoxin that binds to cell-surface receptors and then is activated by furin or furin-like proteases. We genetically engineered proaerolysin by replacing the furin-cleavage sequence with a prostate-specific antigen-selective sequence. The recombinant modified proaerolysin was expressed and purified from Aeromonas salmonicida in good yields and purity. Recombinant modified proaerolysin had no furin sensitivity and markedly increased prostate-specific antigen sensitivity relative to wild-type proaerolysin. Human prostate cancer cells were significantly more sensitive to recombinant modified proaerolysin in the presence of active prostate-specific antigen when compared with the absence of prostate-specific antigen or the presence of potent prostate-specific antigen inhibitors. Most normal human cells with the exception of prostate and renal epithelial cells showed very low sensitivity to recombinant modified proaerolysin. Our results suggest that recombinant modified proaerolysin is a potent prostate-specific antigen-sensitive protoxin that deserves further development for regional therapy of benign and malignant prostate growths.",
keywords = "Proaerolysin, Prostate cancer, Prostate-specific antigen",
author = "Ravibhushan Singh and Browning, {Jeff L.} and Ralph Abi-Habib and Kevin Wong and Williams, {Simon A.} and Rosemina Merchant and Denmeade, {Samuel R} and Buckley, {Thomas J.} and Frankel, {Arthur E.}",
year = "2007",
month = "8",
doi = "10.1097/CAD.0b013e3280bad82d",
language = "English (US)",
volume = "18",
pages = "809--816",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity

AU - Singh, Ravibhushan

AU - Browning, Jeff L.

AU - Abi-Habib, Ralph

AU - Wong, Kevin

AU - Williams, Simon A.

AU - Merchant, Rosemina

AU - Denmeade, Samuel R

AU - Buckley, Thomas J.

AU - Frankel, Arthur E.

PY - 2007/8

Y1 - 2007/8

N2 - Native proaerolysin is a channel-forming bacterial protoxin that binds to cell-surface receptors and then is activated by furin or furin-like proteases. We genetically engineered proaerolysin by replacing the furin-cleavage sequence with a prostate-specific antigen-selective sequence. The recombinant modified proaerolysin was expressed and purified from Aeromonas salmonicida in good yields and purity. Recombinant modified proaerolysin had no furin sensitivity and markedly increased prostate-specific antigen sensitivity relative to wild-type proaerolysin. Human prostate cancer cells were significantly more sensitive to recombinant modified proaerolysin in the presence of active prostate-specific antigen when compared with the absence of prostate-specific antigen or the presence of potent prostate-specific antigen inhibitors. Most normal human cells with the exception of prostate and renal epithelial cells showed very low sensitivity to recombinant modified proaerolysin. Our results suggest that recombinant modified proaerolysin is a potent prostate-specific antigen-sensitive protoxin that deserves further development for regional therapy of benign and malignant prostate growths.

AB - Native proaerolysin is a channel-forming bacterial protoxin that binds to cell-surface receptors and then is activated by furin or furin-like proteases. We genetically engineered proaerolysin by replacing the furin-cleavage sequence with a prostate-specific antigen-selective sequence. The recombinant modified proaerolysin was expressed and purified from Aeromonas salmonicida in good yields and purity. Recombinant modified proaerolysin had no furin sensitivity and markedly increased prostate-specific antigen sensitivity relative to wild-type proaerolysin. Human prostate cancer cells were significantly more sensitive to recombinant modified proaerolysin in the presence of active prostate-specific antigen when compared with the absence of prostate-specific antigen or the presence of potent prostate-specific antigen inhibitors. Most normal human cells with the exception of prostate and renal epithelial cells showed very low sensitivity to recombinant modified proaerolysin. Our results suggest that recombinant modified proaerolysin is a potent prostate-specific antigen-sensitive protoxin that deserves further development for regional therapy of benign and malignant prostate growths.

KW - Proaerolysin

KW - Prostate cancer

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=34250846978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250846978&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3280bad82d

DO - 10.1097/CAD.0b013e3280bad82d

M3 - Article

VL - 18

SP - 809

EP - 816

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 7

ER -